Oracle Investment Management
GREENWICH, CTfiles as ORACLE INVESTMENT MANAGEMENT INC
$153m in 17 US stocks at the end of 31 December 2025. The top 10 are 98.0% of the money. It changed about 13.5% of the portfolio this quarter.
Value
$153m
Stocks
17
Top 10 share
98.0%
Turnover
13.5%
What changed this quarter
New
Bought for the first time this quarter.
- Taysha Gene TherapiesTSHA1.0% of the fund
- Edgewise TherapeuticsEWTX0.6% of the fund
- DAY One Biopharmaceuticals I0.6% of the fund
- ARK ETF TRARKG0.4% of the fund
- Tempus AITEM0.3% of the fund
- Hertz Global HoldingsHTZ<0.1% of the fund
Added
Bought more of a stock they already held.
- ArdelyxARDX7.2% of the fund+25%
- BiohavenBHVN5.7% of the fund+4%
- PersonalisPSNL1.8% of the fund+48%
- Sangamo TherapeuticsSGMOQ0.3% of the fund+3%
Cut
Sold some of their stake.
- Teladoc HealthTDOC1.6% of the fund-50%
Sold out
Sold their entire stake.
- Palantir TechnologiesPLTR-100%
- CenteneCNC-100%
- NovavaxNVAX-100%
- Kraneshares TrustKOID-100%
- BiodesixBDSX-100%
Holdings
- Forian
- Share
- 1.9%
- Value
- $3m
- Shares
- 1,366,107
Held
- DAY One Biopharmaceuticals I
- Share
- 0.6%
- Value
- $932,000
- Shares
- 100,000
New
- ARK ETF TRARKG
- Share
- 0.4%
- Value
- $564,915
- Shares
- 19,500
New
- Sangamo TherapeuticsSGMOQ
- Share
- 0.3%
- Value
- $435,012
- Shares
- 1,035,742
+3%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| GeneDx HoldingsWGS | 75.4% | $115m | 884,654 | Held |
| ArdelyxARDX | 7.2% | $11m | 1,872,624 | +25% |
| BiohavenBHVN | 5.7% | $9m | 772,181 | +4% |
| QuidelOrthoQDEL | 2.2% | $3m | 118,291 | Held |
| Forian | 1.9% | $3m | 1,366,107 | Held |
| PersonalisPSNL | 1.8% | $3m | 339,343 | +48% |
| Teladoc HealthTDOC | 1.6% | $2m | 354,338 | -50% |
| Taysha Gene TherapiesTSHA | 1.0% | $1m | 265,000 | New |
| Cava GroupCAVA | 0.7% | $1m | 17,100 | Held |
| Edgewise TherapeuticsEWTX | 0.6% | $951,482 | 38,343 | New |
| DAY One Biopharmaceuticals I | 0.6% | $932,000 | 100,000 | New |
| ARK ETF TRARKG | 0.4% | $564,915 | 19,500 | New |
| Sangamo TherapeuticsSGMOQ | 0.3% | $435,012 | 1,035,742 | +3% |
| BiogenBIIB | 0.3% | $424,488 | 2,412 | Held |
| Tempus AITEM | 0.3% | $384,238 | 6,507 | New |
| TeslaTSLA | 0.1% | $224,860 | 500 | Held |
| Hertz Global HoldingsHTZ | <0.1% | $77,100 | 15,000 | New |
Options (5)
- Teladoc Health
- Type
- Call
- Value
- $5m
- Contracts
- 650,000
- Novavax
- Type
- Call
- Value
- $4m
- Contracts
- 600,000
- Ardelyx
- Type
- Call
- Value
- $3m
- Contracts
- 600,000
- Biohaven
- Type
- Call
- Value
- $3m
- Contracts
- 232,900
- Pfizer
- Type
- Call
- Value
- $622,500
- Contracts
- 25,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| Teladoc Health | Call | $5m | 650,000 |
| Novavax | Call | $4m | 600,000 |
| Ardelyx | Call | $3m | 600,000 |
| Biohaven | Call | $3m | 232,900 |
| Pfizer | Call | $622,500 | 25,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Value is up 32.1% since 30 June 2025.
Where the money is
Health care95.7%
Retail & consumer0.9%
Technology0.3%
Other3.2%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.